Pages that link to "Q34975651"

The following pages link to Review and evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry (Q34975651):

Displaying 39 items.

• An age-dependent physiologically based pharmacokinetic/pharmacodynamic model for the organophosphorus insecticide chlorpyrifos in the preweanling rat (Q23911011) (← links)
• Pharmacokinetic and pharmacodynamic factors that can affect sensitivity to neurotoxic sequelae in elderly individuals (Q24815657) (← links)
• Aging and the environment: a research framework (Q24815677) (← links)
• Determination of no-observed effect level (NOEL)-biomarker equivalents to interpret biomonitoring data for organophosphorus pesticides in children (Q28387646) (← links)
• Gender and manganese exposure interactions on mouse striatal neuron morphology (Q28391734) (← links)
• Human milk biomonitoring data: interpretation and risk assessment issues (Q31006357) (← links)
• The acquisition and application of absorption, distribution, metabolism, and excretion (ADME) data in agricultural chemical safety assessments (Q31041215) (← links)
• Incorporation of pharmacokinetic and pharmacodynamic data into risk assessments (Q33519666) (← links)
• An assessment of the interindividual variability of internal dosimetry during multi-route exposure to drinking water contaminants (Q34374608) (← links)
• Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: implications for assessing children's risks from environmental agents (Q35624622) (← links)
• Incorporating pharmacokinetic differences between children and adults in assessing children's risks to environmental toxicants (Q35827686) (← links)
• Risk assessment of chemicals and pharmaceuticals in the pediatric population: a workshop report (Q36128969) (← links)
• Computational pharmacokinetics during developmental windows of susceptibility (Q36195215) (← links)
• Addressing Early Life Sensitivity Using Physiologically Based Pharmacokinetic Modeling and In Vitro to In Vivo Extrapolation. (Q36657666) (← links)
• Dispelling urban myths about default uncertainty factors in chemical risk assessment--sufficient protection against mixture effects? (Q37004073) (← links)
• Development of good modelling practice for physiologically based pharmacokinetic models for use in risk assessment: the first steps (Q37106742) (← links)
• Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants (Q37146792) (← links)
• Approaches for applications of physiologically based pharmacokinetic models in risk assessment (Q37201545) (← links)
• Characterization of the human kinetic adjustment factor for the health risk assessment of environmental contaminants (Q38137867) (← links)
• Gender-specific differences in the central nervous system's response to anesthesia (Q38170002) (← links)
• Role of the cytochrome P450 enzyme system in veterinary pharmacokinetics: where are we now? Where are we going? (Q39742342) (← links)
• Approaches to acrylamide physiologically based toxicokinetic modeling for exploring child-adult dosimetry differences (Q40148266) (← links)
• Sex Differences in Human and Animal Toxicology. (Q40452643) (← links)
• Age-specific absolute and relative organ weight distributions for Fischer 344 rats (Q43755705) (← links)
• Assessing the impact of child/adult differences in hepatic first-pass effect on the human kinetic adjustment factor for ingested toxicants (Q43878472) (← links)
• Evaluation of the potential impact of pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and lactation (Q44523640) (← links)
• Evaluation of the potential impact of age- and gender-specific pharmacokinetic differences on tissue dosimetry (Q44824434) (← links)
• Toxicological analysis points to a lower tolerable daily intake of melamine in food. (Q45987479) (← links)
• Age-specific absolute and relative organ weight distributions for B6C3F1 mice (Q46683945) (← links)
• Guidance on the risk assessment of substances present in food intended for infants below 16 weeks of age (Q47159532) (← links)
• Chemical partitioning of fine particle-bound As, Cd, Cr, Ni, Co, Pb and assessment of associated cancer risk due to inhalation, ingestion and dermal exposure. (Q47774703) (← links)
• Role of biokinetics in risk assessment of drugs and chemicals in children. (Q47983196) (← links)
• Estimation of interindividual pharmacokinetic variability factor for inhaled volatile organic chemicals using a probability-bounds approach. (Q51627234) (← links)
• Leveraging human genetic and adverse outcome pathway (AOP) data to inform susceptibility in human health risk assessment. (Q52687647) (← links)
• Physiologically based pharmacokinetic model use in risk assessment--Why being published is not enough. (Q53399970) (← links)
• Assessing the impact of the duration and intensity of inhalation exposure on the magnitude of the variability of internal dose metrics in children and adults (Q58402056) (← links)
• Development of growth equations from longitudinal studies of body weight and height in the full term and preterm neonate: From birth to four years postnatal age (Q64125406) (← links)
• Age differences in biological monitoring of chemical exposure: a tentative description using a toxicokinetic model (Q79661599) (← links)
• Evaluation of the impact of the exposure route on the human kinetic adjustment factor (Q85244229) (← links)